Annie P. Im

Annie P. Im

Hematology Oncology

5115 Centre Avenue, Hillman Cancer Center
Pittsburgh, PA 15232

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 70 publications

Real-world treatment and outcomes in hairy cell leukemia: a multicenter retrospective cohort including BRAF inhibitor therapy.

Real-world treatment and outcomes in hairy cell leukemia: a multicenter retrospective cohort including BRAF inhibitor therapy.

Journal: Leukemia & lymphoma

Published: June 12, 2026

All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia.

All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia.

Journal: The New England journal of medicine

Published: June 03, 2026

Rapid Metagenomic Sequencing of Bronchoalveolar Lavage Fluid for Diagnosis of Infection in Patients With Hematologic Malignancies and Pulmonary Complications.

Rapid Metagenomic Sequencing of Bronchoalveolar Lavage Fluid for Diagnosis of Infection in Patients With Hematologic Malignancies and Pulmonary Complications.

Journal: CHEST pulmonary

Published: February 09, 2026

Marrow Microenvironmental Pathobiology and Therapeutic Opportunities for TP53-Mutated Myelodysplastic Syndrome/Acute Myeloid Leukemia.

Marrow Microenvironmental Pathobiology and Therapeutic Opportunities for TP53-Mutated Myelodysplastic Syndrome/Acute Myeloid Leukemia.

Journal: Cancers

Published: December 30, 2025

Challenging a clinical dogma with multimodal machine learning: a retrospective analysis of transplant mismatched donor selection.

Challenging a clinical dogma with multimodal machine learning: a retrospective analysis of transplant mismatched donor selection.

Journal: Leukemia

Published: October 28, 2025

Baricitinib for refractory chronic graft-versus-host disease: results of a phase 1/2 study.

Baricitinib for refractory chronic graft-versus-host disease: results of a phase 1/2 study.

Journal: Blood advances

Published: October 27, 2025

Baricitinib for refractory chronic graft-versus-host-disease: Results of a phase 1/2 study.

Baricitinib for refractory chronic graft-versus-host-disease: Results of a phase 1/2 study.

Journal: Blood advances

Published: October 27, 2025

Feasibility and safety of outpatient hypomethylating agent and venetoclax initiation with and without ramp-up for newly diagnosed acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).

Feasibility and safety of outpatient hypomethylating agent and venetoclax initiation with and without ramp-up for newly diagnosed acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).

Journal: Leukemia & lymphoma

Published: April 28, 2025

Longer time from diagnosis to initiation of hypomethylating agents plus venetoclax for acute myeloid leukemia does not worsen survival: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).

Longer time from diagnosis to initiation of hypomethylating agents plus venetoclax for acute myeloid leukemia does not worsen survival: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).

Journal: Haematologica

Published: April 20, 2025

Impact of Donor Age and Donor Cytomegalovirus Serostatus on Outcomes After Related Donor Allogeneic Hematopoietic Stem Cell Transplantation.

Impact of Donor Age and Donor Cytomegalovirus Serostatus on Outcomes After Related Donor Allogeneic Hematopoietic Stem Cell Transplantation.

Journal: American journal of hematology

Published: January 05, 2025

Outcomes of patients with acute myeloid leukemia treated with intensive therapy after failure of venetoclax-inclusive, less-intensive therapy.

Outcomes of patients with acute myeloid leukemia treated with intensive therapy after failure of venetoclax-inclusive, less-intensive therapy.

Journal: Leukemia research

Published: May 13, 2024

Systemic Treatment with the Janus Kinase Inhibitor Baricitinib in Ocular Chronic Graft-versus-Host Disease.

Systemic Treatment with the Janus Kinase Inhibitor Baricitinib in Ocular Chronic Graft-versus-Host Disease.

Journal: Ophthalmology science

Published: March 24, 2024

Showing 1-12 of 70

Last Updated: 09/26/2026